These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 21609650

  • 1. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
    Boyers D, Jia X, Crowther M, Jenkinson D, Fraser C, Mowatt G.
    Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.
    Lancet; 2015 Oct 24; 386(10004):1649-58. PubMed ID: 26231455
    [Abstract] [Full Text] [Related]

  • 10. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T, Thadanipon K, Rattanasiri S, Ingsathit A, McEvoy M, Attia J, Thakkinstian A.
    Br J Haematol; 2020 Feb 24; 188(3):450-459. PubMed ID: 31423574
    [Abstract] [Full Text] [Related]

  • 11. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K.
    Clin J Oncol Nurs; 2019 Apr 01; 23(2):212-216. PubMed ID: 30880797
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE.
    Ter Arkh; 2018 Aug 17; 90(7):70-76. PubMed ID: 30701925
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.
    Allen R, Bryden P, Grotzinger KM, Stapelkamp C, Woods B.
    Value Health; 2016 Aug 17; 19(5):614-22. PubMed ID: 27565278
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP.
    BioDrugs; 2011 Dec 01; 25(6):401-4. PubMed ID: 22050343
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R, Evangelista ML, Amadori S.
    Drugs; 2008 Dec 01; 68(7):901-12. PubMed ID: 18457458
    [Abstract] [Full Text] [Related]

  • 20. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB, Keating GM, Garnock-Jones KP.
    Drugs; 2016 May 01; 76(8):869-78. PubMed ID: 27151255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.